Last reviewed · How we verify
XmAb5871
At a glance
| Generic name | XmAb5871 |
|---|---|
| Sponsor | Xencor, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of the Effect of XmAb®5871 in Patients With Systemic Lupus Erythematosus (PHASE2)
- Study to Evaluate the Effect of XmAb®5871 on Disease Activity in Patients With IgG4-Related Disease (RD) (PHASE2)
- XmAb5871 Bioavailability Study (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |